Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33103128.
- Also identified by DOI 10.1016/j.xcrm.2020.100101 and PMC identifier 7576690.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Tumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We employ TEP-derived RNA panels, determined by <b>swarm intelligence, to detect and monitor glioblastoma</b>. We assessed specificity by comparing the spliced RNA profile of TEPs from glioblastoma patients with multiple sclerosis and brain metastasis patients (validation series, n = 157; accuracy, 80%; AUC, 0.81 [95% CI, 0.74-0.89; p < 0.001]). Second, analysis of patients with glioblastoma versus asymptomatic healthy controls in an independent validation series (n = 347) provided a detection accuracy of 95% and AUC of 0.97 (95% CI, 0.95-0.99; p < 0.001). Finally, we developed the digitalSWARM algorithm to improve monitoring of glioblastoma progression and demonstrate that the TEP tumor scores of individual glioblastoma patients represent tumor behavior and could be used to distinguish false positive progression from true progression (validation series, n = 20; accuracy, 85%; AUC, 0.86 [95% CI, 0.70-1.00; p < 0.012]). In conclusion, TEPs have potential as a minimally invasive biosource for blood-based diagnostics and monitoring of glioblastoma patients.
Medical subject headings
- Blood Platelets
- Brain Neoplasms
- Glioblastoma
- Monitoring, Physiologic
- Multiple Sclerosis
- RNA, Neoplasm